The Need: Addressing the Growing Threat of Gram-Negative Bacterial Infections

Gram-negative bacterial pathogens, including Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae, are responsible for more than 35% of common hospital-acquired infections. These nosocomial infections lead to severe pneumonia, urinary tract infections, surgical site infections, and bloodstream infections. Alarmingly, over 70% of these infections are now resistant to commonly used antibiotics, posing a significant challenge to public health. With antibiotic resistance on the rise, there is an urgent need for innovative therapies that can effectively combat Gram-negative bacteria.

The Technology: Combining Aminocoumarin and Polymyxin Compounds

Our technology offers a groundbreaking solution in the form of a pharmaceutical composition that combines two key components: (1) an aminocoumarin compound, such as novobiocin, clorobiocin, or coumermycin, and (2) a polymyxin compound, like polymyxin B or polymyxin E. The synergistic action of these compounds enables an effective strategy to combat Gram-negative bacterial infections, including those resistant to conventional antibiotics. These pharmaceutical compositions can be administered through various routes, such as parenteral, oral, intranasal, or topical, providing flexibility in treatment.

Commercial Applications: Versatile Applications of the Technology

The technology's pharmaceutical compositions find wide-ranging applications in the medical field, including:

• Treatment of urinary tract infections, meningeal infections, eye infections, lung infections, and bacteremia caused by Gram-negative bacteria.
• Effective therapy for nosocomial infections, reducing the spread of antibiotic-resistant bacteria in healthcare settings.
• Combatting bacterial infections in both human and non-human animals.

Benefits/Advantages: Advancing Antibiotic Treatment

The integration of aminocoumarin and polymyxin compounds in our pharmaceutical compositions offers several benefits, including:

• Effectiveness against Gram-negative bacteria, even in the presence of antibiotic resistance, providing a new line of defense against these pathogens.
• Reduced toxic side effects in comparison to monotherapies with individual compounds, ensuring a safer treatment experience for patients.
• Increased inhibition of DNA gyrase by aminocoumarin compounds relative to conventional antibiotics, enhancing their antimicrobial potential.
• Flexible administration options (parenteral, oral, intranasal, or topical), facilitating ease of use and adherence to treatment protocols.
• Potential for a single pharmaceutical composition comprising both compounds, simplifying dosing and administration procedures.

In conclusion, our innovative technology offers a powerful and versatile solution to combat the growing threat of Gram-negative bacterial infections. By combining aminocoumarin and polymyxin compounds, our pharmaceutical compositions provide an effective and safe approach to tackle antibiotic-resistant bacteria, advancing the field of antibiotic treatment and safeguarding public health.